Showing 1-2 of 2 results
Haiwei Lian M.D.
Funded: 07-01-2015 through 06-30-2018
Funding Type: International Scholar
Institution Location: Wuhan, China
Institution: Wuhan University School of Medicine

MYCN-driven neuroblastoma accounts for about 30% of neuroblastomas and is associated with an extremely poor prognosis. Casein Kinase 2 (CK2) is an enzyme that is currently in clinical trials to treat multiple cancers. However, its efficacy on MYCN-driven neuroblastoma remains unknown. Dr. Lian's research aims to test if CK2 inhibition can serve as a new strategy to treat MYCN-driven neuroblastoma. A portion of this grant was named for The Amanda Rozman Pediatric Cancer Research Fund created in memory of Amanda Rozman and honors her courageous battle with neuroblastoma by funding promising new treatments and clinical trials in the area of translational research.

Hui Zhang Ph.D., M.D.
Funded: 07-01-2014 through 06-30-2017
Funding Type: International Scholar
Institution Location: Guangzhou, China
Institution: The First Affiliated Hospital of Guangzhou Medical University

Though cure rates have improved dramatically, geographic inequities in childhood acute lymphoblastic leukemia (ALL) therapy remain evident between developed vs. low-middle income countries. In China, about 7,700 newly-diagnosed children with ALL every year receive therapy thanks to the coverage provided by a special national health insurance scheme established in 2010. With the drastic increase in access to clinical care, the challenge is now shifting from remedying the inability to pay for ALL therapy to delivering better therapy and improving outcome. Dr. Zhang is working to bring improved therapy to China. This represents an unprecedented opportunity for translational research of childhood ALL in China, with potential impacts for a large number of patients.